{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercalcaemia/background-information/causes/","result":{"pageContext":{"chapter":{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field 01190b67-68f6-473a-9b0f-0a1a446ba42c --><h2>What causes it?</h2><!-- end field 01190b67-68f6-473a-9b0f-0a1a446ba42c -->","summary":"","htmlStringContent":"<!-- begin item 13a71aa2-bf7a-468b-95b0-83d6d8d1e3fe --><!-- begin field dcafa212-dffe-484d-baac-7bb21f29f475 --><p><strong>There are multiple possible underlying causes of hypercalcaemia, the two most common being primary hyperparathyroidism and malignancy (which together account for 90% of cases). Be aware that more than one underlying condition may co-exist </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>]<strong>.</strong></p><ul><li><strong>Primary hyperparathyroidism</strong><ul><li>This is the commonest cause of hypercalcaemia and usually presents as mild asymptomatic hypercalcaemia, due to excessive and inappropriate secretion of parathyroid hormone (PTH) secreted by the parathyroid glands [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>Increased secretion of PTH alters the regulation of serum calcium by increasing bone resorption and renal calcium reabsorption, and indirectly by increasing intestinal calcium absorption [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>There are different possible sources of excess PTH:<ul><li>A solitary parathyroid adenoma is the cause in about 85% of cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li><li>Less commonly, secretion is from multiglandular parathyroid hyperplasia, ectopic parathyroid adenomas, or parathyroid cancer (very rare) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li></ul></li><li>It may be associated with rare inherited endocrinopathies including multiple endocrine neoplasia (MEN) type 1 and type 2A syndromes, hyperparathyroidism jaw tumour syndrome, and familial isolated hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li></ul></li><li><strong>Malignancy</strong><ul><li>Malignancy is the second most common cause of hypercalcaemia. It is often a late finding in advanced malignancy, and the underlying disease is often known when hypercalaemia is identified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].<ul><li>Malignancy-related hypercalcaemia should be suspected if there is rapid-onset hypercalcaemia, severe hypercalcaemia, and/or symptoms. Typically serum PTH levels are suppressed or undetectable [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li></ul></li><li>Hypercalcaemia can occur in malignancy <em>with or without </em>skeletal metastases. There are two main mechanisms of hypercalcaemia in malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Twycross et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jick, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>]:<ul><li>In 80% the mechanism is secretion of parathyroid hormone-related protein and other circulating factors by the tumour (a paraneoplastic syndrome).</li><li>In 20% bone metastases cause osteolysis and release of skeletal calcium, for example in breast cancer and multiple myeloma.</li></ul></li><li>The malignancies most commonly associated with hypercalcaemia include breast, lung, oesophageal, head and neck, skin, cervix, breast, kidney, and bladder cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Seccareccia, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li></ul></li><li><strong>Drugs</strong><ul><li>Thiazide diuretics<ul><li>Hypercalcaemia is usually mild and caused by reduced urinary calcium excretion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>Calcium levels usually return to normal after discontinuation of the thiazide unless there is an underlying primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>].</li></ul></li><li>Lithium<ul><li>Lithium may directly stimulate PTH secretion and increase renal calcium reabsorption. The effects are typically reversed on drug withdrawal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>Lithium decreases the sensitivity of the calcium-sensing receptor to calcium, and it may also unmask pre-existing primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>].</li></ul></li><li>Vitamin D <ul><li>Hypercalcaemia may be caused by excessive oral intake of vitamin D, its metabolites and analogues, or excessive topical application of potent vitamin D analogues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li></ul></li><li>Vitamin A<ul><li>Hypercalcaemia can be caused by taking excessive amounts of oral vitamin A for weeks or months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li><li>Other manifestations of vitamin A toxicity include dermatitis, alopecia, and hepatic dysfunction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Chan et al, 1997</a>].</li></ul></li><li>Calcium co-prescribed with antacids or calcium and vitamin D preparations (so-called 'calcium-alkali syndrome') [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].<ul><li>This syndrome is characterized by severe hypercalcaemia, renal impairment, and metabolic alkalosis.</li></ul></li></ul></li><li><strong>Granulomatous diseases</strong><ul><li>These include sarcoidosis, tuberculosis, leprosy, histoplasmosis, candidiasis, coccidiomycosis, berylliosis, eosinophilic granuloma, and silicone-induced granuloma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>The mechanism is thought to be ectopic production of calcitriol by cells in the lungs and lymph nodes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li></ul></li><li><strong>Renal</strong><ul><li>In chronic renal failure, low calcium levels cause parathyroid gland hypertrophy (secondary hyperparathyroidism). Tertiary hyperparathyroidism occurs when the hypertrophied glands start to produce excess unregulated PTH autonomously, causing calcium levels to rise inappropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li><li>In end-stage renal disease and/or people receiving renal replacement therapy, treatment with calcium and calcitriol or vitamin D analogues may precipitate hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>Following renal transplantation, hypercalcaemia may occur due to pre-existing parathyroid hyperplasia and the restoration of 1,25-dihydroxyvitamin D<sub>3 </sub>production by the transplanted kidney [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li><li>During the recovery phase of acute kidney injury (AKI), hypercalcaemia may result from rebound increases in levels of PTH and 1,25-dihydroxyvitamin D<sub>3</sub>. If the AKI was due to rhabdomyolysis, hypercalcaemia also results from subsequent mobilization of calcium deposited in muscle and soft tissue [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li></ul></li><li><strong>Familial hypocalciuric hypercalcaemia</strong><ul><li>This is a rare, benign, autosomal dominant disorder of calcium metabolism caused by a mutation in the calcium-sensing receptor leading to a general calcium insensitivity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>].</li><li>It is characterized by mild, lifelong asymptomatic hypercalcaemia, hypophosphataemia, reduced renal calcium excretion, and a normal or slightly elevated PTH level [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li><li>Hypercalcaemia is present from birth, but the condition may not be detected until adulthood [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li></ul></li><li><strong>Non-parathyroid endocrine diseases</strong><ul><li>Thyrotoxicosis<ul><li>The cause is excessive osteoclast activity with associated excess bone resorption relative to bone mineralization [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li><li>Hypercalcaemia is usually mild and returns to normal with correction of thyroid function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li></ul></li><li>Addison's disease<ul><li>This is a rare cause of hypercalcaemia resulting from increased calcium resorption from bone and dehydration which can occur in untreated adrenal insufficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li></ul></li><li>Phaeochromocytoma<ul><li>This can cause hypercalcaemia due to the production of parathyroid hormone-related peptide (PTHrP) and co-existing primary hyperparathyroidism in MEN type 2A syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li></ul></li><li>Vasoactive intestinal polypeptide hormone-producing tumour (VIPoma, a type of islet cell tumour)<ul><li>When hypercalcaemia is present, it can be severe and the mechanism is unclear. Clinical features include large-volume diarrhoea and hypokalaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li><li>VIPomas can co-exist with primary hyperparathyroidism in MEN type 1 syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>].</li></ul></li></ul></li><li><strong>Immobility</strong><ul><li>Hypercalcaemia may occur in immobilized people with accelerated bone turnover such as Paget's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Singer, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].<ul><li>Hypercalcaemia is an unusual complication of Paget's disease, and occurs in people with more generalized skeletal disease.</li><li>Enhanced osteoclast activity and diminished osteoblast activity results in overall increased bone resorption. In some cases, hypercalcaemia of another cause is worsened by immobility.</li></ul></li></ul></li></ul><!-- end field dcafa212-dffe-484d-baac-7bb21f29f475 --><!-- end item 13a71aa2-bf7a-468b-95b0-83d6d8d1e3fe -->","topic":{"id":"c0ab4dd9-cccf-54af-a952-765aa048de1d","topicId":"897bf773-43ef-4092-a798-d9eb4cbcb9cc","topicName":"Hypercalcaemia","slug":"hypercalcaemia","lastRevised":"Last revised in August 2019","chapters":[{"id":"dfffab44-62c8-5590-8bad-e41f249a89e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fbfb541d-eae2-5916-af42-b77d9c9ab401","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3c7aba33-da1a-580a-b896-fb6026eb2ad8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d715de-b85d-534b-8c6f-0cf5f59814c2","slug":"changes","fullItemName":"Changes"},{"id":"48c69505-e62a-5332-a3ad-fd44bb64bd34","slug":"update","fullItemName":"Update"}]},{"id":"0105d032-866a-57c0-8c83-2f54f2b7b491","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"989b5402-77d7-5cd9-86a7-979019eba917","slug":"goals","fullItemName":"Goals"},{"id":"5d8d7c84-01cb-59e9-a02e-489cb32e799e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7c39bf4-b50f-51f7-ad27-49c431acf456","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb69f34-e184-554d-a518-e9d59c4f95de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d7060151-5501-51fc-b393-844af2c2ca54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d4d8cad-82f7-5bb5-8c59-b47873b845b2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28f41cc2-0513-5841-9fa6-1a59bb557452","slug":"definition","fullItemName":"Definition"},{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes"},{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c5e2134-d0b1-5804-bc33-86db97dfc33b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dc0291c2-c628-503e-a7f7-7f3fa1362b62","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5771a8e-2f1e-53ad-a2fc-322152fc3a3e","slug":"confirmation","fullItemName":"Confirmation"},{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment"}]},{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","fullItemName":"Management","slug":"management","subChapters":[{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause"},{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy"},{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care"}]},{"id":"4017390d-3b38-5741-8d16-22624da35f3d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ec3d6b5-1818-5b5f-af66-bd097d709bf2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"847bb207-2cb8-5e5f-b3e8-ee87440a71cd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"47a9d106-98da-5683-9641-88d123a8d071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a8225b5a-40b4-53e5-9095-0953daa376fa","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c60f947f-6176-53b3-9484-54b966632a77","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b6a6af13-45f8-5258-a611-6d8306bbe251","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f68489fb-5d5f-5342-94a0-3979f632012b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}